Jonathan Hauptman

6.7k total citations · 2 hit papers
20 papers, 4.2k citations indexed

About

Jonathan Hauptman is a scholar working on Pharmacology, Endocrinology, Diabetes and Metabolism and Cell Biology. According to data from OpenAlex, Jonathan Hauptman has authored 20 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pharmacology, 7 papers in Endocrinology, Diabetes and Metabolism and 6 papers in Cell Biology. Recurrent topics in Jonathan Hauptman's work include Pharmacology and Obesity Treatment (17 papers), Muscle metabolism and nutrition (6 papers) and Diabetes Treatment and Management (4 papers). Jonathan Hauptman is often cited by papers focused on Pharmacology and Obesity Treatment (17 papers), Muscle metabolism and nutrition (6 papers) and Diabetes Treatment and Management (4 papers). Jonathan Hauptman collaborates with scholars based in United States, Switzerland and United Kingdom. Jonathan Hauptman's co-authors include Mark Boldrin, Lars Sjöström, Jarl Torgerson, Charles Lucas, Steven B. Heymsfield, Jain Chung, Sarah Hampl, Jean‐Pierre Chanoine, Craig L. Jensen and David C. Robbins and has published in prestigious journals such as JAMA, American Journal of Clinical Nutrition and Diabetes Care.

In The Last Decade

Jonathan Hauptman

19 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study

2004 1.3k citations Jarl Torgerson, Jonathan Hauptman et al. Diabetes Care profile →
Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat

1999 705 citations Michael Davidson, Jonathan Hauptman et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonathan Hauptman United States	14	3.0k	2.0k	1.7k	630	502	20	4.2k
Mark Boldrin United States	16	2.2k 0.7×	1.9k 0.9×	1.3k 0.8×	582 0.9×	426 0.8×	22	3.5k
Charles Lucas United States	20	1.3k 0.4×	1.4k 0.7×	890 0.5×	382 0.6×	257 0.5×	58	2.9k
Priscilla Hollander United States	38	2.8k 0.9×	4.9k 2.4×	1.7k 1.0×	1.7k 2.7×	175 0.3×	96	6.9k
Matilde Sanchez United States	10	1.4k 0.5×	905 0.4×	729 0.4×	274 0.4×	90 0.2×	12	2.0k
Kerstin Kempf Germany	27	420 0.1×	716 0.4×	776 0.5×	193 0.3×	304 0.6×	69	2.1k
Chrysi Koliaki Greece	28	167 0.1×	1.1k 0.5×	1.5k 0.9×	758 1.2×	331 0.7×	52	3.8k
Michael EJ Lean United Kingdom	12	446 0.1×	743 0.4×	413 0.2×	226 0.4×	200 0.4×	22	1.6k
Louise Bishop United States	8	148 0.0×	605 0.3×	1.7k 1.0×	310 0.5×	1.4k 2.7×	9	2.6k
Christine Beebe United States	13	168 0.1×	1.2k 0.6×	737 0.4×	524 0.8×	410 0.8×	17	2.2k
Alexandre A. da Silva United States	29	218 0.1×	904 0.4×	1.3k 0.8×	389 0.6×	383 0.8×	68	4.1k

Countries citing papers authored by Jonathan Hauptman

Since Specialization

Citations

This map shows the geographic impact of Jonathan Hauptman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Hauptman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Hauptman more than expected).

Fields of papers citing papers by Jonathan Hauptman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Hauptman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Hauptman. The network helps show where Jonathan Hauptman may publish in the future.

Co-authorship network of co-authors of Jonathan Hauptman

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Hauptman. A scholar is included among the top collaborators of Jonathan Hauptman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Hauptman. Jonathan Hauptman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jacob, Stephan, et al.. (2009). Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obesity and Metabolism. 11(4). 361–371. 55 indexed citations

Ahnen, Dennis J., et al.. (2007). Effect of Orlistat on Fecal Fat, Fecal Biliary Acids, and Colonic Cell Proliferation in Obese Subjects. Clinical Gastroenterology and Hepatology. 5(11). 1291–1299. 13 indexed citations

Anderson, James W., et al.. (2006). Obesity: Low-Dose Orlistat Effects on Body Weight of Mildly to Moderately Overweight Individuals: A 16 Week, Double-Blind, Placebo-Controlled Trial. Annals of Pharmacotherapy. 40(10). 1717–1723. 34 indexed citations

Chanoine, Jean‐Pierre, Sarah Hampl, Chad D. Jensen, Mark Boldrin, & Jonathan Hauptman. (2005). Effect of Orlistat on Weight and Body Composition in Obese Adolescents. A Randomized Controlled Trial. ACC Current Journal Review. 14(9). 7–7. 9 indexed citations

Chanoine, Jean‐Pierre, Sarah Hampl, Craig L. Jensen, Mark Boldrin, & Jonathan Hauptman. (2005). Effect of Orlistat on Weight and Body Composition in Obese Adolescents. JAMA. 293(23). 2873–2873. 412 indexed citations

Torgerson, Jarl, Jonathan Hauptman, Mark Boldrin, & Lars Sjöström. (2004). XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. Diabetes Care. 27(1). 155–161. 1284 indexed citations breakdown →

Reaven, Gerald M., Karen R. Segal, Jonathan Hauptman, Mark Boldrin, & Charles Lucas. (2001). Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. The American Journal of Cardiology. 87(7). 827–831. 77 indexed citations

Hauptman, Jonathan, et al.. (2001). Orlistat in the Long-term Treatment of Obesity in Primary Care Settings.. Journal of Cardiopulmonary Rehabilitation. 21(1). 53–53. 1 indexed citations

Hauptman, Jonathan. (2000). Orlistat: Selective Inhibition of Caloric Absorption Can Affect Long-Term Body Weight. Endocrine. 13(2). 201–206. 23 indexed citations

10.

Hauptman, Jonathan. (2000). Orlistat in the Long-term Treatment of Obesity in Primary Care Settings. Archives of Family Medicine. 9(2). 160–167. 286 indexed citations

11.

Segal, Karen R., Charles Lucas, Jonathan Hauptman, & Priscilla Hollander. (2000). Effect of weight loss with orlistat on cardiovascular disease risk prediction in type 2 diabetes. Diabetes Research and Clinical Practice. 50. 292–292. 1 indexed citations

12.

Heymsfield, Steven B., Karen R. Segal, Jonathan Hauptman, et al.. (2000). Effects of Weight Loss With Orlistat on Glucose Tolerance and Progression to Type 2 Diabetes in Obese Adults. Archives of Internal Medicine. 160(9). 1321–1321. 264 indexed citations

13.

Davidson, Michael, Jonathan Hauptman, Mario DiGirolamo, et al.. (1999). Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat. JAMA. 281(3). 235–235. 705 indexed citations breakdown →

14.

Zhi, Jianguo, et al.. (1999). Long‐Term Systemic Exposure of Orlistat, a Lipase Inhibitor, and Its Metabolites in Obese Patients. The Journal of Clinical Pharmacology. 39(1). 41–46. 66 indexed citations

15.

Hill, James O., Jonathan Hauptman, James W. Anderson, et al.. (1999). Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. American Journal of Clinical Nutrition. 69(6). 1108–1116. 225 indexed citations

16.

Hauptman, Jonathan, et al.. (1998). Prospective comparison of four sampling methods (cystocentesis, bladder mucosal swab, bladder mucosal biopsy, and urolith culture) to identify urinary tract infections in dogs with urolithiasis. Journal of the American Animal Hospital Association. 34(5). 423–430. 13 indexed citations

17.

Hollander, Priscilla, Steven C. Elbein, Irl B. Hirsch, et al.. (1998). Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study. Diabetes Care. 21(8). 1288–1294. 472 indexed citations

18.

Zhi, Jianguo, Angela T. Melia, Roberto Guerciolini, et al.. (1994). Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clinical Pharmacology & Therapeutics. 56(1). 82–85. 210 indexed citations

19.

Ertel, Norman H., et al.. (1983). Adrenergic blockade in pheochromocytoma.. PubMed. 143(12). 2245–6. 12 indexed citations

20.

Hauptman, Jonathan. (1983). Pheochromocytoma Resistant to a-Adrenergic Blockade. Archives of Internal Medicine. 143(12). 2321–2321. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact